Veeva Systems has secured Eli Lilly and Company's commitment to deploy Veeva Vault CRM globally, while announcing that President and Chief Customer Officer Thomas D. Schwenger will depart in October 2026, to be succeeded by Dan Rizzo as EVP of Sales, Consulting, and Services. The Eli Lilly win reinforces the thesis that top 20 pharma are increasingly willing to consolidate critical commercial workflows on Veeva's platform, tying directly into consensus expectations for continued subscription and services growth. Wall Street analysts anticipate higher upcoming quarterly earnings and revenue for Veeva, with the company's narrative projecting $4.7 billion revenue and $1.4 billion earnings by 2029, requiring 12.7% yearly revenue growth and an earnings increase of about $0.5 billion from $941.7 million today. Some analysts expect Veeva to reach about US$4.5 billion in revenue and US$1.3 billion in earnings by 2029, while the most cautious voices see AI agents, especially in Safety and clinical workflows, as a swing factor that could reshape those forecasts. The leadership change in Sales and Services does not appear to materially shift the biggest short term risk around customer concentration and contract renewals.
Veeva Systems Inc Class AEli Lilly's global commitment to Veeva Vault CRM strengthens subscription and services growth outlook
Eli Lilly and CompanyEli Lilly commits to Veeva Vault CRM globally, indicating adoption of Veeva's platform
Salesforce.com Inc